ROIV ▲ +1.6% - Roivant Sciences Ltd. $ROIV ROIVW - Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. Roivant Sciences gained 1.6% following Priovant's announcement of FDA approval for LISRAYA™ (brepocitinib) as a treatment for adults with dermatomyositis. The drug is now available for purchase in the U.S. market, representing a significant milestone for the company's pipeline and a potential new revenue driver. 27-AUG-2026 03:28 PM ET